Velcade (bortezomib) for injection therapy for early relapsed prostate cancer.
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs Bortezomib (Primary) ; Bicalutamide; Flutamide; Goserelin; Leuprorelin
- Indications Prostate cancer
- Focus Therapeutic Use
- 17 Oct 2018 Status changed to discontinued due to low accrual
- 31 Aug 2018 Biomarkers information updated
- 27 Apr 2012 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.